Aktis Oncology (AKTS) CEO details initial stock and option holdings

Rhea-AI Filing Summary

Aktis Oncology, Inc. (AKTS) filed an initial insider ownership report for President and CEO, and director, Matthew Roden as of January 8, 2026. He directly beneficially owns 91,998 shares of common stock and holds several stock option awards. These include options to purchase 578,277 shares at $1.91 per share that have fully vested, as well as options for 558,095 shares at $3.66, 618,757 shares at $9.33, and 394,280 shares at $18 per share, which vest over time according to specified schedules tied to his continued service with the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

RODEN MATTHEW

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	91,998	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	04/14/2031	Common Stock	578,277	$1.91	D
Stock Option (Right to Buy)	(2)	11/15/2032	Common Stock	558,095	$3.66	D
Stock Option (Right to Buy)	(3)	10/10/2034	Common Stock	618,757	$9.33	D
Stock Option (Right to Buy)	(4)	01/07/2036	Common Stock	394,280	$18	D

Explanation of Responses:

1. These options have vested in full.

2. 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

3. 25% of the original number of shares subject to the option vested on October 9, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

4. 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthew Roden	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filing for Aktis Oncology (AKTS) report?

The Form 3 reports initial beneficial ownership of Aktis Oncology, Inc. securities by Matthew Roden, who is the company’s President, CEO, and a director, as of January 8, 2026.

How many Aktis Oncology (AKTS) common shares does Matthew Roden beneficially own?

Matthew Roden directly beneficially owns 91,998 shares of Aktis Oncology, Inc. common stock, according to the Form 3.

What stock options are reported for Matthew Roden in the Aktis Oncology (AKTS) Form 3?

The filing lists four stock option grants: options for 578,277 shares at $1.91, 558,095 shares at $3.66, 618,757 shares at $9.33, and 394,280 shares at $18 per share, each exercisable for common stock.

Which of Matthew Roden’s Aktis Oncology (AKTS) options are already fully vested?

The Form 3 notes that the option to purchase 578,277 shares at $1.91 per share has vested in full.

How do the remaining Aktis Oncology (AKTS) stock options for Matthew Roden vest?

For one grant, 25% vested on November 1, 2023, with 1/48th vesting monthly thereafter; for another, 25% vested on October 9, 2025, with 1/48th vesting monthly. A later grant provides that 25% will vest on January 8, 2027, with 1/48th vesting monthly thereafter, all subject to his continuous service.

Does the Aktis Oncology (AKTS) Form 3 indicate whether this is a stock purchase or sale?

No purchase or sale transaction codes are shown; the Form 3 presents holdings and vesting terms rather than reporting new buy or sell transactions.

What roles does Matthew Roden hold at Aktis Oncology (AKTS) according to the filing?

The filing identifies Matthew Roden as a Director and as an Officer, serving as President and CEO of Aktis Oncology, Inc.